SGS Opens Central & Eastern Europe Offices for Clinical Trial Management.
Geneva, Switzerland-April 25, 2008-As a further step in the initiative to expand its Global Clinical Development (GCD) services, SGS Life Science Services has opened three new offices in Poland, Czech Republic, and Romania. The offices located in Prague, Warsaw, and Bucharest, respectively, will provide services for clinical trial monitoring, study feasibility, and site selection, as well as support the regulatory aspects in these countries.
“The opening of the new offices addresses the request of many of our sponsors to conduct trials in Central and Eastern Europe in order to benefit from the vast pool of treatment naïve patients, faster enrolment times, and the cost benefits these countries offer,” said Luc Braeken, vice president of global clinical development. “Highly qualified and motivated investigators, low drop out rates of enrolled patients, and the high quality of the clinical data are additional advantages of conducting trials in Central and Eastern Europe.”
The offices are staffed with highly knowledgeable teams with broad experience in conducting clinical trials in the pharmaceutical and CRO industry as well as in academia. Lead by seasoned MDs, the teams cover a wide range of therapeutic areas with special emphasis in CNS, infectious disease, and cardiovascular disease, SGS’ areas of core expertise.Complementary services including project management, data management and statistics, regulatory affairs, and medical affairs will be provided from SGS’ main office for GCD in Belgium with more than 400 people.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.